ArticleFrontiers in genetics2015
Rapid evolution of silver nanoparticle resistance in Escherichia coli.
Article in Frontiers in genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 296 citations in OpenAlex.
- Triple Threat: Elucidating Evolution Under Antibiotic, Metal, and Phage Pressure inEcology and evolution · 2026Article
- Bacterial Adaptive Responses to Green and Chemically Synthesized Silver Nanoparticles: Implications for Resistance Development.Nanomaterials (Basel, Switzerland) · 2026Article
- Rapid Evolution of Ionic Silver Resistance inMicroorganisms · 2026Article
- Green-Synthesized vs. Chemical Silver Nanoparticles: A Comparative Study onMicroorganisms · 2026Article
- Research on Silver-Based Wound Dressing: An Ontological Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Contact-Dependent Antibacterial Performance of Silver Nanoparticles Encapsulated in Collagen-Based Gels.Journal of functional biomaterials · 2026Article
- Chemical characterization and improvement property of Hydnocarpus wightianus-synthesized iron nanoparticles on lung infection in mice model.Discover nano · 2026Article
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- Emerging strategies of bacterial adaptation mechanisms to silver and metal oxide nanomaterials.FEMS microbiology reviews · 2026Review
- Adaptive transcriptional remodeling ofNpj complexity · 2026Article
- Silver Nanoparticles Templated by the M13 Phage Exhibit High Antibacterial Activity against Gram-Negative Pathogens and a Reduced Rate of Bacterial Resistance In Vitro.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Gallium Liquid Metal Nanoparticles as Agents to Treat Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2025Article
- Silver Nanoparticle-Antibiotic Combinations: A Strategy to Overcome Bacterial Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Evolution of cross-tolerance to metals in yeast.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Idiosyncratic evolvability among single-point ribosomal mutants towards multi-aminoglycoside resistance.PLoS genetics · 2025Article
- Surface-Enhanced Raman Spectroscopy for Adenine Detection in Five Selected Bacterial Strains Under Stress Conditions.Sensors (Basel, Switzerland) · 2025Article
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- Hydrogel Containing Biogenic Silver Nanoparticles andPharmaceutics · 2025Article
- The Impact of Silver Nanoparticles' Size on Biofilm Eradication.International dental journal · 2025Article
- Potential Antibiotic Resurgence: Consecutive Silver Nanoparticle Applications Gradually Increase Bacterial Susceptibility to Antibiotics.ACS omega · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent exponential increase in the use of engineered nanoparticles (eNPs) means both greater intentional and unintentional exposure of eNPs to microbes. Intentional use includes the use of eNPs as biocides. Unintentional exposure results from the fact that eNPs are included in a variety of commercial products (paints, sunscreens, cosmetics). Many of these eNPs are composed of heavy metals or metal oxides such as silver, gold, zinc, titanium dioxide, and zinc oxide. It is thought that since metallic/metallic oxide NPs impact so many aspects of bacterial physiology that it will difficult for bacteria to evolve resistance to them. This study utilized laboratory experimental evolution to evolve silver nanoparticle (AgNP) resistance in the bacterium Escherichia coli (K-12 MG1655), a bacterium that does not harbor any known silver resistance elements. After 225 generations of exposure to the AgNP environment, the treatment populations demonstrated greater fitness vs. control strains as measured by optical density (OD) and colony forming units (CFU) in the presence of varying concentrations of 10 nm citrate-coated silver nanoparticles (AgNP) or silver nitrate (AgNO3). Genomic analysis shows that changes associated with AgNP resistance were already accumulating within the treatment populations by generation 100, and by generation 200 three mutations had swept to high frequency in the AgNP resistance stocks. This study indicates that despite previous claims to the contrary bacteria can easily evolve resistance to AgNPs, and this occurs by relatively simple genomic changes. These results indicate that care should be taken with regards to the use of eNPs as biocides as well as with regards to unintentional exposure of microbial communities to eNPs in waste products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.